OS Therapies announces OST-HER2 trial achieves primary endpoint

OS Therapies (OSTX) announced data from a Phase 2b clinical trial of OST-HER2 – the company’s HER2-targeted immunotherapy candidate in the rare pediatric-designated indication of prevention of recurrent, fully resected, lung metastatic osteosarcoma. The data demonstrate statistically significant results in the primary endpoint of the study, 12-month event free survival, where an event is defined as the recurrence of metastatic osteosarcoma, in OST-HER2-treated patients when compared with the leading published historical comparable control group. Further as of the most recent follow up, the data show a trend in favor of OST-HER2-treated patients in overall survival at the one-year and two-year interim timepoints of the ongoing three-year overall survival secondary endpoint. Notably, all patients who achieved the primary 12-month EFS endpoint remain alive. 33% for OST-HER2 vs. 20% for historical control.